Evidence map›Paper›PMID 34060895›Full record

ArticleAntimicrobial agents and chemotherapy2021

Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing

Amelia Bhatnagar, Sandra Boyd, Sarah Sabour, Janine Bodnar, Elizabeth Nazarian, Nadine Peinovich, Christine Wagner, Bradley Craft, Paula Snippes Vagnone, Justin Simpson and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Microbiology spectrum · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. HighMicrobiology spectrum · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. An NDM-ProducingOpen forum infectious diseases · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Amelia BhatnagarDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sandra BoydDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sarah SabourDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Janine BodnarWadsworth Center, New York State Department of Health, Albany, New York, USA.
Elizabeth NazarianWadsworth Center, New York State Department of Health, Albany, New York, USA.
Nadine PeinovichWadsworth Center, New York State Department of Health, Albany, New York, USA.
Christine WagnerWadsworth Center, New York State Department of Health, Albany, New York, USA.
Bradley CraftMinnesota Department of Health, St. Paul, Minnesota, USA.
Paula Snippes VagnoneMinnesota Department of Health, St. Paul, Minnesota, USA.
Justin SimpsonTennessee Department of Health, Nashville, Tennessee, USA.
Victoria N StoneTennessee Department of Health, Nashville, Tennessee, USA.
Michelle TherrienTennessee Department of Health, Nashville, Tennessee, USA.
Allen BatemanWisconsin State Laboratory of Hygiene, Madison, Wisconsin, USA.
Danielle LowerWisconsin State Laboratory of Hygiene, Madison, Wisconsin, USA.
Jennifer Y HuangDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Stephanie GumbisDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
David LonswayDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Joseph D LutgringDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Maria KarlssonDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Allison C BrownDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Centers for Disease Control and Prevention · USNew York State Department of Health · USTennessee Department of Health · USMinnesota Department of Health · US

Funding

HHS | Centers for Disease Control and Prevention (CDC)
6 · The paper itself

Abstract

Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing

Indexed as

Aztreonambeta-LactamasesAnti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeDrug CombinationsDrug Resistance, MicrobialHumansLaboratoriesMicrobial Sensitivity TestsAnti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeDrug Combinationsantibiotic resistanceantimicrobial combinationsaztreonam-avibactambeta-lactamasescarbapenemasesEnterobacteralesMBLsusceptibility testing

Identifiers

PMID34060895
PMCPMC8284474
OpenAlexW3165714513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.